CATEGORIES: Systemic Lupus Erythematosus
First posted April 1, 2022, Updated July 11, 2022; Recruiting
The purpose of this Phase 3 study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.
To Learn More Contact
Call RemeGen at 301-284-1015 or by email to RC18_SLEstudy@remegenbio.com
ClinicalTrials.gov identifier (NCT number): NCT05306574